Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy p ...
Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England ...
Danish drugmaker Lundbeck explores acquisition of Xeris Biopharma, sending Xeris shares to 2019 highs as markets react to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results